Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT06668181 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT06668181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06668181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Recruiting
Start date
March 11, 2025
Completion date
July 31, 2030
Enrollment
40 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

enthesitis-related arthritis, juvenile psoriatic arthritis